

10/58062

RECEIVED 26 MAY 2006

ATTORNEY DOCKET NO.: 36920-0416-00-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Patrick Gerard JOHNSTON  
Daniel LONGLEY

Application No: Not yet assigned  
(International Application No: PCT/GB2004/005008)

Filed: (International Application: 26 November 2004 (26.11.2004))

For: COMBINATION THERAPY


Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

The present application is a 35 U.S.C. § 371 of PCT/GB2004/005008. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate as a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. A copy of the International Search Report is enclosed.

It is believed that copies of the references have been or will be forwarded by the International Search Authority. The Examiner is encouraged to contact the undersigned if reference copies have not been received.

|  |  |
|--|--|
| CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10  |  |
| EXPRESS MAIL Mailing Label Number: EV545927646US<br>Date of Deposit: May 26, 2006  |  |
| I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. |  |
| <br>Signature of person mailing page:<br>KAREN M. SPINA<br>Type or print name of person  |  |

10/580662

IAP9RECUPERTO 26 MAY 2006

INFORMATION DISCLOSURE STATEMENT  
US NATL. PHASE OF PCT/GB2004/005008

ATTORNEY DOCKET NO. 36920-0416-00-US

The Examiner is respectfully requested to review the items listed on the substitute PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This Information Disclosure Statement is being submitted concurrently with the filing of the above-referenced application. Therefore, no certification, petition or fee is required. However, should a fee be due, authorization is hereby provided to charge Deposit Account No. 50-0573.

Respectfully submitted,

Gerard Patrick JOHNSTON et al.

BY

  
DANIEL A. MONACO  
Registration No. 30,480  
DRINKER BIDDLE & REATH LLP  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
TEL: (215) 988-3312  
FAX: (215) 988-2757  
*Attorney for Applicants*

**SUBSTITUTE FORM PTO-1449**

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**'APO Rec'd PCT/RTO 26 MAY 2006**

## **INFORMATION DISCLOSURE STATEMENT**

**APPLICANT:**  
Gerard Patrick JOHNSTON et  
al.

**FILING DATE**  
Herewith  
(I.A. 26 November 2004)

**GROUP**  
Not Yet Assigned

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

|        |    |   |
|--------|----|---|
| /M.N./ | AA | Allen et al., "Activation of Fas-mediated cell death in response to 5-fluorouracil and antifolate chemotherapies", <i>Proceedings of the American Research Annual Meeting</i> , 44: 418, 2003.                |
| /M.N./ | AB | Backu et al., "Thymidylate synthase inhibition triggers apoptosis via caspases-8 and 9 in both wild-type and mutant p53 colon cancer cell lines", <i>European Journal of Cancer</i> , 39(9): 1310-1317, 2003. |
| /M.N./ | AC | Kim et al., "p53-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, C1-IB-MECA", <i>Biochemical Pharmacology</i> , 63(5): 871-880, 2002.                                |
|        |    |   |
|        |    |   |
|        |    |   |

**EXAMINER** /Meera Natarajan/ **DATE CONSIDERED** 07/16/2008

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|                                  |  |  |  |
|----------------------------------|--|--|--|
| SUBSTITUTE FORM PTO-1449         | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO.<br>36920-0416-00-US               | SERIAL NO.<br>Not Yet Assigned<br>(I.A. PCT/GB2004/005008) |
| INFORMATION DISCLOSURE STATEMENT |  | PCT Rec'd/PCT/PTO 26 MAY 2006                      |  |
|                                  |  | APPLICANT:<br>Gerard Patrick JOHNSTON et al.       |  |
|                                  |  | FILING DATE<br>Herewith<br>(I.A. 26 November 2004) | GROUP<br>Not Yet Assigned                                  |

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|        |    |   |
|--------|----|---|
| /M.N./ | AA | Allen et al., "Activation of Fas-mediated cell death in response to 5-fluorouracil and antifolate chemotherapies", <i>Proceedings of the American Research Annual Meeting</i> , 44: 418, 2003.                |
| /M.N./ | AB | Backu et al., "Thymidylate synthase inhibition triggers apoptosis via caspases-8 and 9 in both wild-type and mutant p53 colon cancer cell lines", <i>European Journal of Cancer</i> , 39(9): 1310-1317, 2003. |
| /M.N./ | AC | Kim et al., "p53-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, C1-IB-MECA", <i>Biochemical Pharmacology</i> , 63(5): 871-880, 2002.                                |
|        |    |   |
|        |    |   |
|        |    |   |

100

/Meera Natarajan/

#### **RATE CONSIDERED**

07/16/2008

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.